Point-of-Care Testing
With Clarity and Confidence
Point-of-care testing with SARS-CoV-2, SARS-CoV-2 & Flu A+B,* Flu A+B, RSV and Group A Strep assays, providing rapid diagnostic testing in a convenient, portable instrument.
Contact Us
Why choose the rapid diagnostic testing of the BD Veritor™ Plus System?
Complexity slows care. The BD Veritor™ Plus System simplifies it.
Clear
Visual inspection of unclear or faint lines is subjective and may lead to incorrect diagnosis and treatment.
Simple
No maintenance, no calibration and intuitive workflows help enable your team to test with more confidence at point of care, closest to the patient.
Fast
Remove guesswork by providing digitally-interpreted results in 15 minutes or less.**
Discover how easy sample collection can simplify testing workflows for reliable results you can act on
The BD Veritor™ Plus System is a versatile and efficient rapid diagnostic testing program with robust support, giving you the ability to provide reliable results and decide on a course of treatment for your patients quickly at the point of care, and in the environment that makes them most comfortable.
In acute care settings—where health complexities, rapid decision-making, and workflow systems converge—it becomes easy to appreciate the effortlessness with which the BD Veritor™ Plus System accommodates changes in workflow and capacity.
Point-of-care rapid diagnostic testing has become increasingly essential, and the BD Veritor™ Plus System can make a big difference. In-house respiratory tract infection testing with reliable, rapid results means staff is more prepared for rapid triage; able to detect and diagnose infections and even treat a patient in the same visit.
As a community organization, you have many priorities, but we know you have people to protect. You require flexibility, simplicity and reliability, so that those you serve and those who work for you can continue to enjoy life. With the BD Veritor™ Plus System, you can identify certain respiratory infections and then take steps to limit the spread of these respiratory infections throughout your organization and the community.
Trust BD for the Digital Difference
Integrating workflows for reliable results you can act on.
Digital Clarity. Unambiguous positive/negative display which may help to reduce result interpretation errors and streamline diagnosis.
Flexible workflow options. Includes Walk Away mode or Analyze Now mode.
Rapid results. Delivers digitally read results in 15 minutes or less,** supporting timely clinical decisions.
Cost-effective. No service contracts, maintenance or calibration needed for device lifetime.
Easy to use. No monthly calibration required, operated with single-button functionality.
Contact a Sales Representative to get your organization’s
diagnostic testing program started today
Professional Care Testing
The BD Veritor™ Plus System enhances point-of-care testing for COVID-19, Flu A+B, COVID-19 & Flu A+B,* RSV and Group A Strep, providing rapid diagnostic testing in a convenient, portable instrument.
Get Support
See how BD supports you with tools, education, and training—enabling a streamlined point-of-care experience for those you serve, and confidence in your results.
RSV=respiratory syncytial virus; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
**Result processing times for each BD Veritor™ assay are 15 minutes for the SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays, 10 minutes for Flu A+B and RSV assays, and 5 minutes for the Group A Strep assay.
BD, the BD Logo, and BD Veritor are trademarks of Becton, Dickinson and Company or its affiliates. © 2026 BD. All rights reserved.
bd.com